(Reuters) -Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S.

The move comes amid an ongoing investigation into multiple patient deaths tied to Sarepta’s gene therapy […] To keep reading ... opinions, images, photos, graphics, graphs, charts, animations, and ...

This brand-new Tundra TRD, riddled with cool accessories, will become yours thanks to the nonprofit organization A Race ...

The Washington Post News Service with Bloomberg budget for Sunday, Aug. 3, 2025. All stories have moved unless otherwise noted. The News Service hours of operation are as follows, with exceptions for ...

A study evaluating a pioneering lentivirus (LV)-mediated gene therapy trial for classical Fabry disease showed promising results over five years, indicating a potential breakthrough in treatment ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy ...

The patient, who was in a trial for a limb girdle gene therapy, is the third person to die this year after receiving a Sarepta gene therapy.

Youth with congenital deafness treated with gene therapy showed better progress on certain hearing measures than counterparts treated with cochlear implantation in a cohort study from China. Gene ...

The manufacturing-related rejection also delays a key test of the new FDA leadership’s support for cell and gene therapy against rare diseases.

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy. The company's stock has been under pressure for weeks ...

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments ...

Over 5 years of treatment in hemophilia B patients, gene therapy research shows sustained factor IX activity and safety.